Pharvaris
Update in progressPHVS (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Pharvaris N.V. is a late-stage biopharmaceutical company focused on developing and commercializing therapies for rare, unmet needs in bradykinin-mediated diseases, including angioedema. Its lead candidate, deucrictibant, is a small-molecule bradykinin B2-receptor antagonist for attacks in hereditary or acquired angioedema. Pharvaris is in Phase 3 for treatment and prevention, with extended-release tablet and immediate-release capsule forms. Founded 2015, based in Zug, Switzerland.
Company score
- Sentiment
- 0.43
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.41
- Governance
- 0.07
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.14
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.29
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationSwitzerland
- CEOMr. Berndt Axel Edvard Modig CPA, M.B.A.
- Founded2015
- Employees148
- Websitepharvaris.com
Identifiers
- ISINNL00150005Y4
- FIGIBBG00YYCW1N8
- CIK0001830487